PASG News and Press, Passage Bio Inc. From 04/05/21

- Krabbe disease, a rare lysosomal storage disorder, has no approved disease-modifying treatment options - Urgency for effective treatment underscored by European Commission designation for investigational gene therapy PBKR03 - Global Phase 1/2 trial – GALax-C &...

The first patient has been dosed in Passage Bio's (PASG) Phase 1/2 clinical trial program for PBGM01 for the treatment of infantile GM1 gangliosidosis (GM1). Imagine-1 is a dose-escalation study of PBGM01 administered by a single injection into the cisterna magna in pediatric subjects with ea...

– PBGM01 advancement to clinical development represents key milestone for Passage Bio as a clinical-stage company – PHILADELPHIA, April 01, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developin...

PHILADELPHIA, March 25, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in three upcoming virtual inve...

Passage Bio (PASG) announces that it has appointed Eliseo  Salinas as the company’s chief research & development ((R&D)) officer.Salinas joins the company from Acadia Pharmaceuticals, where he served as chief scientific officer ((CSO)) and senior vice presid...

PHILADELPHIA, March 22, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced it has appointed Eliseo O. Salinas, M.D., MSc, as the comp...

SIOX has promising results in its gene therapy programs. Not only is the Parkinson's disease program showing impressive results, but recent developments on the rare disease front are also very encouraging. I work through these developments and then turn to the company's valuation ...

Passage Bio (PASG) announces the U.S. FDA has granted Fast Track designation to the company’s three lead investigational gene therapies: PBGM01 for the treatment of GM1 gangliosidosis ((GM1)), PBFT02 for frontotemporal dementia with granulin mutations (FTD-GRN), and PBKR03 for Krabbe d...

PHILADELPHIA, March 08, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced the U.S. Food and Drug Administration (FDA) has granted F...

Passage Bio, Inc. (PASG) on Friday filed for a common stock offering of up to $125M.The company also filed for a mixed shelf offering.The filing does not necessarily indicate that a sale has begun, or will occur in the future.SEC Form S-3Passage Bio shares closed Friday up 2.1% to $...